'whatever the outcome'21 Nov 2017 20:10
''we will continue to pursue our strategy of geographic and product diversification, coupled with a sharp focus on achieving profitability within the current financial year. We believe this strategy will ensure that, whatever the outcome of the UK disputes, Premaitha is a business that will succeed in the rapidly expanding global market for NIPT and clinical genetic testing."